Regnery, Sebastian
de Colle, Chiara
Eze, Chukwuka
Corradini, Stefanie
Thieke, Christian
Sedlaczek, Oliver
Schlemmer, Heinz-Peter
Dinkel, Julien
Seith, Ferdinand
Kopp-Schneider, Annette
Gillmann, Clarissa
Renkamp, C. Katharina
Landry, Guillaume
Thorwarth, Daniela
Zips, Daniel
Belka, Claus
Jäkel, Oliver
Debus, Jürgen
Hörner-Rieber, Juliane
Funding for this research was provided by:
Universitätsklinikum Heidelberg
Article History
Received: 3 January 2023
Accepted: 3 April 2023
First Online: 4 May 2023
Change Date: 8 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13014-023-02294-5
Declarations
:
: The PUMA trial was approved by the local ethics board of the Medical Faculty at Heidelberg University (coordinating trial center, IRB number: S-701/2021) and by the local ethic boards at the trial centers in Munich and Tuebingen.
: Not applicable.
: J. H.-R. and S. K. received speaker fees from ViewRay Inc. J. H.-R. received speaker fees from Pfizer Inc., travel reimbursement from ViewRay Inc., IntraOP Medical and Elekta Instrument AB as well as grants from IntraOP Medical and Varian Medical Systems outside the submitted work. J.D. received grants from View Ray Inc., from CRI – The Clinical Research Institute GmbH, Accuray Incorporated, Accuray International Sàrl, RaySearch Laboratories AB, Vision RT limited, Astellas Pharma GmbH, Astra Zeneca GmbH, Solution Akademie GmbH, Ergomed PLC Surrey Research Park, Merck Serono GmbH, Siemens Healthcare GmbH, Quintiles GmbH, Pharmaceutecal Research Associates GmbH, Boehringer Ingelheim Pharma GmbH Co, PTW-Freiburg Dr. Pychlau GmbH, Nanobiotix A.A. and IntraOP Medical outside the submitted work. Travel costs were covered by Elekta for C. G. C.B. and S.C. have received research grants and speaker fees/travel support from Elekta, Viewray and Brainlab.